APA (7th ed.) Citation

Ingram, J. R., Fujita, H., Gottlieb, A. B., Lev-Tov, H., Prens, E., Sayed, C. J., . . . Orenstein, L. A. V. (2025). Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. Pain & Therapy, 14(6), 1861. https://doi.org/10.1007/s40122-025-00779-7

Chicago Style (17th ed.) Citation

Ingram, John R., et al. "Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials." Pain & Therapy 14, no. 6 (2025): 1861. https://doi.org/10.1007/s40122-025-00779-7.

MLA (9th ed.) Citation

Ingram, John R., et al. "Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials." Pain & Therapy, vol. 14, no. 6, 2025, p. 1861, https://doi.org/10.1007/s40122-025-00779-7.